NCT03375710已完成不适用
A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Heart Failure System in (New York Heart Association) NYHA Class III Heart Failure Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Efficacy: Accuracy
研究概览
简要总结
This is a prospective, multi-center, open-label, single-arm feasibility trial to assess device safety and efficacy of the Cordella™ Heart Failure System in 10 NYHA Class III heart failure patients who will receive the Cordella™ Sensor implant.
详细描述
The objectives of this study are to establish that the Cordella™ Sensor can be safely delivered, deployed, and remain stable within the target pulmonary artery (PA) segment through 30 days post-implant as well as to measure the accuracy of Cordella™ Sensor PA pressure measurements compared with fluid-filled catheter PA pressure measurements obtained by standard right heart catheterization (RHC) at 90 days post implant. Safety measures will include the frequency and rates of adverse events, both overall and for each specific event, which will be collected throughout the study. Subjects will remain in this trial for 24 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has given written informed consent
- •Male or female, at least 18 years of age
- •Diagnosis of HF ≥ 3 months with either preserved or reduced left ventricular ejection fraction (LVEF)
- •Diagnosis of NYHA Class III HF at the time of Screening with at least 1 HF-related hospitalization, HF treatment in a hospital day-care setting, or urgent outpatient clinic HF visit within the last year
- •Subjects must be receiving appropriate medical management of HF for 3 months prior to Screening and clinically stable for at least 1 month prior to study entry
- •Subjects with a Body Mass Index (BMI) < 35 kg/mL2 and chest circumference < 1050 mm
- •Subjects with right pulmonary artery branch diameter sized between 14 mm and 20 mm (target Sensor implant site) over a length of at least 30mm
- •Subjects with distance between target implant site (right PA branch) and ventral thoracic skin surface of < 12cm
- •Subjects who are physically able to hold the myCordella™ Patient Reader unit (approximate weight 600g) against the ventral thoracic surface for up to 2 minutes per day while in a seated. position, as well as dock and undock the myCordella™ Patient Reader
- •Subjects with sufficient eyesight, hearing, and mental capacity to respond to the myCordella™ Patient Reader's audio/visual cues and operate the myCordella™ Patient Reader.
- •Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home
- •Subject agrees to return to the treating Investigator for all scheduled follow up visits and can return to the hospital for follow up
- •Subject compliance as defined by data collection and transmissions at least 5 days a week (does not have to be consecutive days) using the myCordella™ Hub & Peripherals for at least 1 week during the screening period
排除标准
- •Subjects with primary pulmonary hypertension.
- •Subjects with an active infection at the Sensor Implant Visit
- •Subjects with history of recurrent (> 1) pulmonary embolism or deep vein thrombosis
- •Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of the Screening Visit
- •Subjects whereby RHC or computed tomography pulmonary angiography (CTPA) is contraindicated
- •Subjects with a Cardiac Resynchronization Device (CRT), Internal Cardiac Defibrillator (ICD) or pacemaker (if implanted less than 6 months or has more than a single lead), or Left Ventricular Assist Device (LVAD)
- •Any major surgery within 30 days of the Sensor Implant Visit.
- •Subjects with a Glomerular Filtration Rate (GFR) <30 ml/min or who are on chronic renal dialysis
- •Specific liver enzymes [Aspartate Aminotransferase (AST) (SGOT), and Alanine Aminotransferase (ALT) (SGPT) >3 times the upper limit of normal
- •Subjects likely to undergo lung and/ or heart transplantation within 24 months of the Screening Visit.
- •Subjects with congenital heart disease or mechanical/tissue right heart valve(s)
- •Subjects with known coagulation disorders
- •Subjects with a hypersensitivity or allergy to platelet aggregation inhibitors including aspirin, clopidogrel, prasugrel, and ticagrelor; or patients unable to take dual antiplatelet or anticoagulants for one month post implant
- •Subjects enrolled in another investigational trial.
- •Known history of life threatening allergy to contrast dye.
- •Subjects who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or subjects with a history of non-compliance
- •Subjects with large metal implants/prostheses or any other materials in the thoracic cavity that may interfere with the Cordella™ Pulmonary Artery Sensor System performance
- •Subjects with an indwelling inferior vena cava (IVC) filter
- •Subjects who are pregnant or breastfeeding
- •Subjects whose clinical condition, in the opinion of the Investigator, makes them an unsuitable candidate for the study
- •Severe illness, other than heart disease, which would limit survival to <1 year
- •Subjects who have had intractable arrhythmias within 2 month of the Screening Visit
- •Subjects with patent foramen ovale (PFO)
结局指标
主要结局
Efficacy: Accuracy
时间窗: 90 days
Accuracy of Cordella™ Sensor PA pressure measurements, compared to standard-of-care fluid-filled catheter PA pressure measurements obtained by standard Right Heart Catheter
Safety Freedom form Adverse events
时间窗: 30 days
Freedom from adverse events associated with use of the Cordella™ HF System
次要结局
- Frequency of Adverse Events(30 days and 2 years)
- Device/system-related complications(30 days and 2 years)
- Accuracy of Cordella™ sensor pressure measurements(2 years)
- Percentage of device success(90 days)
- Change in Pulmonary Artery (PA) pressure(90 days)
- Heart Failure (HF) Hospitalizations(90 days)
- Frequency of Adverse Events(30 days and 2 years)
- Device/system-related complications(30 days and 2 years)
- Pressure sensor failure rate(30 days and 2 years)
- Accuracy of Cordella™ sensor pressure measurements(2 years)
- Change in Pulmonary Artery (PA) pressure(90 days)
- Heart Failure (HF) Hospitalizations(90 days)
- Percentage of device success(90 days)
- Quality of Life measured by Kansas City Cardiomyopathy Questionnaire(90 days and 2 years)
- Quality of Life measured by EuroQOL EQ-5D-5L(90 days and 2 years)
- Adherence to regular myCordella™ Peripherals measurements(90 days and 2 years)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
SIRONA 2 Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04012944Endotronix, Inc.81
招募中
1 期
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant EpilepsyEpilepsyDrug Resistant EpilepsySeizures, FocalSeizureSeizure DisorderNCT06388707NaviFUS Corporation8
进行中（未招募）
不适用
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04089059Endotronix, Inc.738
招募中
不适用
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLPrimary Central Nervous System LymphomaNCT06445257Huai'an First People's Hospital30
已完成
3 期
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionInfluenza, HumanNCT01527110GlaxoSmithKline21